Atea Pharmaceuticals SEC filings document the regulatory record of a Nasdaq-listed clinical biopharmaceutical company developing oral antiviral therapies. Form 8-K reports furnish financial results, preliminary financial information, business updates, and exhibit press releases that describe the company’s HCV and HEV antiviral programs.
Proxy and annual meeting filings cover governance matters, director elections, auditor ratification, executive compensation, pay-versus-performance disclosures, and stockholder voting results. The filings also identify Atea’s common stock, par value $0.001 per share, traded under AVIR on The Nasdaq Global Select Market.
Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) filed an 8-K summarising the results of its 20 June 2025 Annual Meeting of Stockholders.
- Quorum: 74,981,407 shares (≈87.6 % of outstanding) were represented in person or by proxy.
- Director elections (Class II, terms expiring 2028):
- Bruno Lucidi - 46,640,587 FOR / 12,559,084 WITHHOLD / 15,781,736 broker non-votes.
- Polly Murphy, DVM, PhD - 41,184,263 FOR / 18,015,408 WITHHOLD / 15,781,736 broker non-votes.
- Bruce Polsky, MD - 46,597,653 FOR / 12,602,018 WITHHOLD / 15,781,736 broker non-votes.
- Auditor ratification: KPMG LLP re-appointed for FY 2025 with 73,766,274 FOR, 1,192,659 AGAINST, 22,474 ABSTAIN; no broker non-votes.
- Say-on-pay (advisory): 46,450,302 FOR, 12,107,029 AGAINST, 642,340 ABSTAIN, 15,781,736 broker non-votes.
All three proposals passed. No other material business was disclosed in the filing.